Differential (Click to cross reference) adverse drug reaction bone marrow suppression carcinoma central nervous system, infection of cladribine complications cost effectiveness disability, neurological efficacy fingolimod gammaglobulin therapy, intravenous herpes zoster iatrogenic neurologic disorders immunosuppressive agents JC virus lymphoma lymphopenia methotrexate mitoxantrone monoclonal antibodies MRI MRI, abnormal multiple sclerosis multiple sclerosis, chronic progressive multiple sclerosis, relapsing multiple sclerosis, treatment of natalizumab opportunistic infection opportunistic infection, CNS outcome research progressive multifocal leucoencephalopathy review article risk factors safety sarcoidosis sarcoidosis, CNS suprasellar lesion thrombocytopenia treatment of neurologic disorder vaccination, neurologic complications with vaccine viral infection viral infection, CNS

Showing articles 0 to 5 of 5 A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010 Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009 Treatment of Refractory Neurosarcoidosis with Cladribine NEJM 350:1798-1799, Tikoo,R.K.,et al, 2004 Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost? JNNP 70:574-579, Bryan,J.,et al, 2001 Cladribine in Treatment of Chronic Progressive Multiple Sclerosis Lancet 344:3-13, Sipe,J.C.,et al, 1994 Showing articles 0 to 5 of 5